KP 46

Drug Profile

KP 46

Alternative Names: FFC11

Latest Information Update: 06 Dec 2005

Price : $50

At a glance

  • Originator Faustus Forschungs Compagnie
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 Nov 2005 Preclinical trials in Cancer in Austria (PO)
  • 23 Feb 1999 An abstract has been added to the pharmacodynamics section
  • 10 Sep 1998 Profile reviewed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top